Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry

This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoa...

Descripción completa

Detalles Bibliográficos
Autores: Montoya-Garcia, MJ, Carbonell-Abella, C, Garcia, MG, Hernández-Cruz, B, Gómez-Vaquero, C, Naranjo, A, Aviñó, RI, Miedes, DM, Muriel, APM, Mora-Fernández, J, Oreiro, SC, Crespo, DO, Llona, MJ, Escobar, CA, Sureda, MMF, Cuadra-Llopart, L, Ramos, MM, Zorrilla, SS, Martinez-Laguna, D, Diaz-Guerra, GM, Cancio-Trujillo, JM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p19415
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/19415
Access Level:acceso abierto
Palabra clave:Adherence
Fracture Liaison Services
Fragility fractures
High-risk fracture
Osteoporosis
Very high-risk fracture
id ES_c9fa4e784564f2fb473b72dfb3fd0880
oai_identifier_str oai:fisabio.fundanetsuite.com:p19415
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM RegistryMontoya-Garcia, MJCarbonell-Abella, CGarcia, MGHernández-Cruz, BGómez-Vaquero, CNaranjo, AAviñó, RIMiedes, DMMuriel, APMMora-Fernández, JOreiro, SCCrespo, DOLlona, MJEscobar, CASureda, MMFCuadra-Llopart, LRamos, MMZorrilla, SSMartinez-Laguna, DDiaz-Guerra, GMCancio-Trujillo, JMAdherenceFracture Liaison ServicesFragility fracturesHigh-risk fractureOsteoporosisVery high-risk fractureThis study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures. Objective To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors. Methods This retrospective, multicenter, population-based observational cohort study included patients aged >= 50 years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk. Results Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72 years in HRF; p < 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures. Conclusion 26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.SPRINGER LONDON LTD2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/19415OSTEOPOROSIS INTERNATIONALISSN: 0937941XISSNe: 14332965reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p194152026-06-11T12:45:17Z
dc.title.none.fl_str_mv Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
title Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
spellingShingle Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
Montoya-Garcia, MJ
Adherence
Fracture Liaison Services
Fragility fractures
High-risk fracture
Osteoporosis
Very high-risk fracture
title_short Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
title_full Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
title_fullStr Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
title_full_unstemmed Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
title_sort Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
dc.creator.none.fl_str_mv Montoya-Garcia, MJ
Carbonell-Abella, C
Garcia, MG
Hernández-Cruz, B
Gómez-Vaquero, C
Naranjo, A
Aviñó, RI
Miedes, DM
Muriel, APM
Mora-Fernández, J
Oreiro, SC
Crespo, DO
Llona, MJ
Escobar, CA
Sureda, MMF
Cuadra-Llopart, L
Ramos, MM
Zorrilla, SS
Martinez-Laguna, D
Diaz-Guerra, GM
Cancio-Trujillo, JM
author Montoya-Garcia, MJ
author_facet Montoya-Garcia, MJ
Carbonell-Abella, C
Garcia, MG
Hernández-Cruz, B
Gómez-Vaquero, C
Naranjo, A
Aviñó, RI
Miedes, DM
Muriel, APM
Mora-Fernández, J
Oreiro, SC
Crespo, DO
Llona, MJ
Escobar, CA
Sureda, MMF
Cuadra-Llopart, L
Ramos, MM
Zorrilla, SS
Martinez-Laguna, D
Diaz-Guerra, GM
Cancio-Trujillo, JM
author_role author
author2 Carbonell-Abella, C
Garcia, MG
Hernández-Cruz, B
Gómez-Vaquero, C
Naranjo, A
Aviñó, RI
Miedes, DM
Muriel, APM
Mora-Fernández, J
Oreiro, SC
Crespo, DO
Llona, MJ
Escobar, CA
Sureda, MMF
Cuadra-Llopart, L
Ramos, MM
Zorrilla, SS
Martinez-Laguna, D
Diaz-Guerra, GM
Cancio-Trujillo, JM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Adherence
Fracture Liaison Services
Fragility fractures
High-risk fracture
Osteoporosis
Very high-risk fracture
topic Adherence
Fracture Liaison Services
Fragility fractures
High-risk fracture
Osteoporosis
Very high-risk fracture
description This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures. Objective To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors. Methods This retrospective, multicenter, population-based observational cohort study included patients aged >= 50 years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk. Results Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72 years in HRF; p < 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures. Conclusion 26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/19415
url https://fisabio.portalinvestigacion.com/publicaciones/19415
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER LONDON LTD
publisher.none.fl_str_mv SPRINGER LONDON LTD
dc.source.none.fl_str_mv OSTEOPOROSIS INTERNATIONAL
ISSN: 0937941X
ISSNe: 14332965
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419438933016576
score 15.811543

Similares en LA Referencia